WO2005012532A1 - Sistema para la producción de proteínas diméricas basado en el sistema de transporte de hemolisina de escherichia coli - Google Patents
Sistema para la producción de proteínas diméricas basado en el sistema de transporte de hemolisina de escherichia coli Download PDFInfo
- Publication number
- WO2005012532A1 WO2005012532A1 PCT/ES2004/070053 ES2004070053W WO2005012532A1 WO 2005012532 A1 WO2005012532 A1 WO 2005012532A1 ES 2004070053 W ES2004070053 W ES 2004070053W WO 2005012532 A1 WO2005012532 A1 WO 2005012532A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid sequence
- peptide
- coli
- sequence
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 92
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 92
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 78
- 239000003228 hemolysin Substances 0.000 title claims abstract description 22
- 108010006464 Hemolysin Proteins Proteins 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 21
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 107
- 230000028327 secretion Effects 0.000 claims abstract description 51
- 238000006471 dimerization reaction Methods 0.000 claims abstract description 46
- 239000002773 nucleotide Substances 0.000 claims abstract description 46
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000012634 fragment Substances 0.000 claims abstract description 28
- 238000010276 construction Methods 0.000 claims abstract description 20
- 230000032258 transport Effects 0.000 claims abstract description 19
- 230000007246 mechanism Effects 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 103
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 83
- 108020004414 DNA Proteins 0.000 claims description 64
- 108020001507 fusion proteins Proteins 0.000 claims description 45
- 102000037865 fusion proteins Human genes 0.000 claims description 45
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 230000027455 binding Effects 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 19
- 101710118538 Protease Proteins 0.000 claims description 15
- 239000000178 monomer Substances 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 12
- 101800001707 Spacer peptide Proteins 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000002955 isolation Methods 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108010013369 Enteropeptidase Proteins 0.000 claims description 5
- 102100029727 Enteropeptidase Human genes 0.000 claims description 5
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 241000589776 Pseudomonas putida Species 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 229920002704 polyhistidine Polymers 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108010074860 Factor Xa Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 230000005754 cellular signaling Effects 0.000 claims description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 230000004957 immunoregulator effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000029142 excretion Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 231100000167 toxic agent Toxicity 0.000 claims description 2
- 239000003440 toxic substance Substances 0.000 claims description 2
- 108091008023 transcriptional regulators Proteins 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 229920001184 polypeptide Polymers 0.000 description 43
- 239000000047 product Substances 0.000 description 28
- 101150024289 hly gene Proteins 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 241000282836 Camelus dromedarius Species 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
- 239000012228 culture supernatant Substances 0.000 description 12
- 229940024171 alpha-amylase Drugs 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000003119 immunoblot Methods 0.000 description 10
- 108090000637 alpha-Amylases Proteins 0.000 description 9
- 102000004139 alpha-Amylases Human genes 0.000 description 9
- 239000000539 dimer Substances 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001641 gel filtration chromatography Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 210000001322 periplasm Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009830 antibody antigen interaction Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- LNQHREYHFRFJAU-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) pentanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(=O)ON1C(=O)CCC1=O LNQHREYHFRFJAU-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960002766 tetanus vaccines Drugs 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100378273 Brachyspira hyodysenteriae acpP gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 101100098690 Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e) hly gene Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 101150044616 araC gene Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 101150021605 hlyA gene Proteins 0.000 description 1
- 102000043381 human DUSP5 Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- SITVSCPRJNYAGV-UHFFFAOYSA-L tellurite Chemical compound [O-][Te]([O-])=O SITVSCPRJNYAGV-UHFFFAOYSA-L 0.000 description 1
- 101150061166 tetR gene Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Definitions
- This invention relates to the production of dimeric recombinant proteins through the use of a protein expression system based on the hemolysin transport system of Escherichia coli.
- fusion proteins that comprise recombinant bi-or multifunctional antibody fragments (minibodies). These fusion proteins have some advantages and can be used for therapeutic or diagnostic purposes. For this reason, various antibody fragment expression systems have been developed. Some of these expression systems are based on the use of Escherichia coli. Different antibody fragments are usually selected and produced in E. coli after cloning of fragments of the variable (V) and constant (C) regions of immunoglobulins (Ig) into filamentous phage or phagemid vectors [Hoogenboom, HR 1997. Designing and optimizing library selection strategies for generating high-affinity antibody Trends in Biotechnology.
- V variable
- C constant regions of immunoglobulins
- Antibodies for targeted gene therapy extracellular gene targeting and intracellular expression Adv Drug Deliv Rev. 31: 153-170; Yokota, T., D. ⁇ . Milenic, M. Whitlo, and J. Schlo 1992. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res. 52: 3402-8].
- Antibody fragments based on a single Ig domain have also been produced in E. coli [Nuttall, SD, RA Irving, and PJ Hudson 2000.
- V HH domains have demonstrated superior stability and solubility and lower immunogenicity [Cortez-Retamozo, V., M. Lauwereys, G. Hassanzadeh Gh, M. Gobert, K. Conrath, S Muyldermans, P. De Baetselier, and H. Revets 2002. Efficient tumor targeting by single-domain antibody fragments of camels Int J Cancer. 98: 456-62; Tauttall, SD, RA Irving, and PJ Hudson 2000. Immunoglobulin NH domains and beyond: design and selection of single-domain binding and targeting reagents Curr Pharm Biotechnol.
- This secretion system is independent of the cellular sec genes and consists of two internal membrane (IM) components, HlyB and HlyD, and the outer membrane (OM) pore, TolC, which are assembled in a large protein complex with a internal hydrophilic canal [Gentschev, L, G. Dietrich, and W. Goebel 2002. The E. coli alpha-hemolysin secretion system and its use in vaccine development Trends Microbiol. 10: 39-45; Koronakis, V., C. Andersen, and C. Hughes 2001. Channel-tunnels Curr Opin Struct Biol. 11: 403-7; Koronakis, V., A. Sharff, E. Koronakis, B.
- the signal recognized by the Hly secretion machinery is located at the C terminal end of HlyA. It has been shown that scFv-HlyA hybrids, which contain a scFv molecule that lacks the N-SP bound to the last HlyA of approximately 23 kDa, are secreted in a functional manner and oxidized by the Hly transporter [Fernández, LA, and V. De Lorenzo 2001. Formation of disulphide bonds during secretion of proteins through the periplasmic-independent type I pathway Mol Microbiol. 40: 332-46; Fernández, LA, I. Sola, L. Enjuanes, and V. de Lorenzo 2000.
- dimerization is a property that is often desired to be engineered in proteins when binding activity is involved (for example, in protein--DN or antigen-antibody interactions), since it can enhance its affinity functional (avidity), or create bispecific molecules [Baxevanis, AD, and CR Vinson 1993. Interactions of coiled coils in transcription factors: where is the specificity? Curr Opin Genet Dev. 3: 278-85; Busch, SJ, and P. Sassonc-Corsi 1990.
- the invention provides a solution to the existing need based on the development of a DNA construct comprising (i) a nucleotide sequence encoding a product of interest; (ii) a nucleotide sequence encoding a dimerization domain; and (iii) a nucleotide sequence encoding Escherichia coli ⁇ -hemolysin (HlyA) or for a fragment of said protein comprising the recognition signal of the secretion mechanism of the E. coli hemolysin transporter system (Hly). .
- one aspect of this invention relates to a DNA construct comprising (i) a nucleotide sequence encoding a product of interest; (ii) a nucleotide sequence encoding a dimerization domain; and (iii) a nucleotide sequence encoding Escherichia coli ⁇ -hemolysin (HlyA) or for a fragment of said protein comprising the signal of recognition of the secretion mechanism of the hemolysin (Hly) transport system of E. coli.
- the invention relates to an expression cassette comprising said DNA construct operatively linked to an expression control sequence.
- the invention relates to a bacterium comprising at least one DNA construct or at least one expression cassette.
- the invention relates to a method for producing a product of interest, in the form of a dimeric fusion protein, which comprises growing said bacterium under conditions that allow the production and excretion to the culture medium of said product of interest in form of a dimeric fusion protein.
- this relates to a method of producing a heterodimeric fusion protein comprising two products of interest.
- the invention relates to a dimeric fusion protein obtainable by expression of at least one nucleic acid sequence contained in at least one ⁇ DN construct.
- Figure 1 illustrates the secretion of the C-HlyA polypeptide containing the ZIP domain.
- Figure 1A shows a schematic representation of the structure of the EHlyA and ZEHlyA polypeptides containing the 23 kDa MyA secretion signal) of the E. coli Hly transporter labeled with the epitope E. The mass of said polypeptides (in kDa) , deduced from its amino acid sequence, is shown on the right.
- FIG. 1 is a schematic representation of the C-HlyA (monomeric) polypeptide labeled with the E epitope and the C- polypeptide
- HlyA (dimeric) marked with the epitope E and containing the ZIP domain (Ig hinge, leucine zipper, 6xhis mark).
- Figure 1C shows the result of the immunoblotting developed with a POD-labeled anti-E monoclonal antibody of secreted (S) and cellular (C) proteins produced after 4 h induction with 0.3 mM IPTG of cultures of E. coli HB2151 cells, grown at 37 ° C- containing plasmid pNDL9J (which codes for HlyB and HlyD) and one of the indicated plasmids, pEHlyA or pZEHlyA.
- the lane-loaded proteins represent those found in approximately 5 ⁇ l of the culture supernatants (S) and those of E. coli (C) cells present in approximately 100 ⁇ l of the same cultures (OD 6 or approximately 2 nm ).
- Figure 2 illustrates the cross-linking of C-HlyA polypeptides secreted with idyl disuccini glutarate (DSG).
- EHlyA and ZEHlyA polypeptides were incubated with DSG, at the indicated concentrations, and subjected to denaturing SDS-PAGE and immunoblotting with POD-labeled anti-E monoclonal antibody (see Example 1, section on Materials and Methods, for more details).
- ZEHlyA intersected with DSG forming a protein band in SDS-PAGE of approximately 66 kDa - about twice the size of its monomer.
- Figure 3 shows the results of gel filtration chromatography of the monomeric and dimeric C-HlyA polypeptides.
- Figure 3A is a graph depicting the elution volume of the EHly ⁇ (circle) and ZEHly ⁇ (triangle) polypeptides separated by gel filtration chromatography (see Example 1, section on Materials and Methods, for more details) together with protein patterns of known mass (squares).
- the mass standards used were thyroglobulin (Mr 670,000), bovine gammablobulin (Mr 158,000), chicken ovalbumin (Mr 44,000) and equine myoglobin (Mr 17,000).
- the presence of EHlyA or ZEHlyA in the eluted fractions was determined by immunoblotting with POD-labeled anti-E monoclonal antibody.
- Figure 3B shows the result of the immunoblotting developed with a POD-labeled anti-E monoclonal antibody of the EHlyA and ZEHlyA polypeptides.
- a schematic representation of EHlyA (monomeric) and ZEHlyA (dimeric) is shown at the top.
- Figure 4 illustrates the secretion of monomeric N HH- HlyA V amy -HlyA) and dimeric (N ⁇ -ZHlyA) polypeptides.
- Figure 4A is a schematic representation of the structure of the N ⁇ -HlyA and Y amy -Z ⁇ ⁇ A polypeptides containing the 23 kDa (hlyA) secretion signal of the E.
- FIG. 4A is a schematic representation of the polypeptide (monomeric) labeled with the epitope E and of the polypeptide N ⁇ ff ⁇ ZHlyA (dimeric) labeled with the epitope E and containing the ZIP domain (Ig hinge, Leucine zipper, 6xhis brand).
- Figure 4C shows the results of a Western blot where the secretion of protein hybrids having N HH and -EHlyA or -ZEHlyA domains is revealed. E.
- coli HB2151 cells carrying one of the indicated plasmids (N ⁇ w ⁇ HlyA or pN ⁇ ⁇ ZHlyA) were induced with IPTG (see Example 1, section on Materials and Methods, for more details), at indicated temperature, and the presence of secreted polypeptides labeled with the epitope E in culture supernatants was determined by immunoblotting with POD-labeled anti-E monoclonal antibody. Full-length N ⁇ myHlyA and N ⁇ m ZHlyA polypeptides were detected in culture supernatants, along with some proteolytic fragments derived therefrom.
- Figure 4D is a graph of the elution volume of the N ⁇ HlyA (circle) and VamyZ ⁇ lyA (triangle) polypeptides separated by gel filtration chromatography, together with protein patterns of known mass (square) and detected with immunoblotting with monoclonal antibody anti-E marked with POD.
- the mass standards used were the same as those used in relation to Figure 3.
- Figure 5 is a graph illustrating the binding activity of monomeric and dimeric N HH- HlyA polypeptides. The binding of ⁇ -amylase by polypeptides N omj Hly ⁇ and N am; , ZhlyA, at the indicated concentrations, was determined by ELISA (see Example 1, section on Materials and Methods, for more details).
- Figure 9 shows the map of plasmid pN ⁇ v ,, ZhlyA.
- the invention provides a DNA construct, hereinafter referred to as the DNA construct of the invention, comprising: a) a first nucleic acid sequence containing the nucleotide sequence encoding a product of interest ; b) a second nucleic acid sequence containing the nucleotide sequence encoding a dimerization domain; and c) a third nucleic acid sequence containing the nucleotide sequence encoding E.
- HlyA coli ⁇ -hemolysin
- Ffly transporter system E. coli
- nucleotide sequence encoding a homologous gene or a nucleotide sequence encoding a variant, natural or artificial, of HlyA or a fragment thereof comprising the recognition signal of the mechanism of secretion of the Hly transport system from E. coli;
- the first nucleic acid sequence contains the nucleotide sequence that codes for a product of interest (gene of interest).
- the product of interest can be eukaryotic, prokaryotic, viral, etc.
- Virtually any peptide or protein that can be expressed recombinantly can be used in the construction of DNA of the invention, for example, enzymes, enzyme inhibitors, hormones, molecules involved in cell adhesion and / or signaling, molecules involved in detection or mareaje, and molecules composed of domains, for example, immunoglobulins, etc.
- said product of interest can be an immunogenic antigen such as a protein or an antigenic fragment thereof originating from a pathogen, for example, from a viral, bacterial, a parasite pathogen, etc., which can cause infections. in humans or animals; a therapeutic agent, for example, a tumor specific antigen, an antigen of an autoimmune disease, etc .; or a molecule immunoregulatory, for example, growth factors, cytokines, such as interleukins, interferons, etc.
- a pathogen for example, from a viral, bacterial, a parasite pathogen, etc.
- a therapeutic agent for example, a tumor specific antigen, an antigen of an autoimmune disease, etc .
- a molecule immunoregulatory for example, growth factors, cytokines, such as interleukins, interferons, etc.
- said product of interest is a mini-native or, defining recombinant mini-antibodies or antibodies as fragments derived from the antibodies constructed by recombinant DNA technology, and that despite their smaller size retain the antigen binding capacity since they maintain the variable domains of immunoglobulin, where the antigen binding areas reside.
- the second nucleic acid sequence contains the nucleotide sequence that codes for a dimerization domain.
- a dimerization domain is a peptide sequence that promotes dimerization in the proteins that contain it.
- any dimerization domain can be used in the construction of DNA of the invention, for example, peptide propellers, containing at least one propeller, or a structure formed by a propeller, a turn and other propeller, etc., structures double coiled coil (coiled coil), and, in general, any peptide sequence that promotes dimerization in the proteins that contain it.
- said dimerization domain comprises the leucine zipper of the yeast GCN4 transcription factor.
- the third nucleic acid sequence comprises the nucleotide sequence encoding E. coli ⁇ -hemolysin (HlyA) or for a fragment of said protein comprising the recognition signal of the secretion mechanism of the Hly transport system of E.
- E. coli or a nucleotide sequence that codes for a homologous gene, or a nucleotide sequence that codes for a natural or artificial variant of HlyA or a fragment thereof comprising the recognition signal of the system secretion mechanism Hly transporter of E. coli.
- the recognition signal of the secretion mechanism of the E. coli Hly transport system appears to be comprised in the carboxyl terminal (C-terminal), specifically within the last 60 amino acids of HlyA.
- the amino acid and nucleotide sequence of E. coli HlyA can be obtained from GeneBank, accession number M10133, where the amino acid nucleotide sequence of HlyB and HlyD can also be obtained.
- said third nucleic acid sequence is constituted by the nucleotide sequence encoding the E. coli HlyA.
- said third nucleic acid sequence comprises a fragment of the E. coli HlyA containing the recognition signal of the secretion mechanism of the E. coli Hly transport system, such as a nucleotide sequence encoding the last 60 amino acids of the H-C C-terminus of E. coli.
- said third nucleic acid sequence is constituted by, or comprises, the nucleotide sequence encoding the last 60 amino acids of the H-C C-terminal end of E. coli.
- said third nucleic acid sequence contains the nucleotide sequence identified as S ⁇ Q ID NO: 1 which codes for a peptide of approximately 23 kDa from the HlyA terminal carboxyl terminus of E. coli whose amino acid sequence is shown in S ⁇ Q ID NO: 2.
- the dimerization domain does not fuse directly to the gene encoding the product of interest but it is advantageous to introduce a spacer (flexible) peptide between the end of the gene encoding the product of interest and the beginning of the dimerization domain.
- the DNA construct of the invention may also contain, in addition, a fourth nucleic acid sequence encoding a spacer peptide located between said first and second nucleic acid sequences, wherein the 5 'end of said fourth nucleic acid sequence is attached to the 3 'end of said first nucleic acid sequence and the 3' end of said fourth nucleic acid sequence is linked to the 5 'end of said second nucleic acid sequence.
- the coding sequence of the product of interest is linked to the dimerization domain by a spacer peptide.
- said spacer peptide is a peptide with structural flexibility. Virtually any peptide with structural flexibility can be used.
- said flexible peptide may contain repeats of amino acid residues, such as Gly-Gly-Gly-Ser, or any other suitable amino acid residue repeat, or the hinge region of an antibody.
- said flexible spacer peptide comprises the hinge region of an antibody and the DNA construct of the invention contains the coding sequence for said flexible peptide.
- said fourth nucleic acid sequence contains the nucleotide sequence identified as S ⁇ Q ID NO: 3 which codes for a 10 amino acid peptide comprising the hinge region of an antibody whose amino acid sequence is shown in the S ⁇ Q ID NO: 4.
- the DNA construct of the invention may contain, if desired, a nucleic acid sequence encoding a peptide that can be used for isolation or purification purposes of the peptide or fusion protein. Therefore, in a particular embodiment, the DNA construct of the invention contains, if desired, a fifth nucleic acid sequence encoding a peptide capable of being used for isolation or purification purposes.
- Virtually any peptide or peptide sequence that allows the isolation or purification of the fusion peptide or protein can be used, for example, a polyhistidine sequence, or a peptide sequence recognized by a monoclonal antibody and which can be used to purify the resulting fusion protein by immunoaffinity chromatography, for example, tag peptides such as c-myc, HA, E, FLAG, etc. [Using Antibodies: A laboratory manual. Ed Harlow and David La e (1999). Cold Spring Harbor Laboratory Press. New Cork Chapter: Tagging proteins. pp. 347-377] and, in general, any other sequence recognized by an antibody.
- Said fifth nucleic acid sequence may be located at any position of the ⁇ DN construct of the invention except in the region corresponding to the C-terminal end of Hly ⁇ since, in that case, it would break the secretion signal.
- said fifth nucleic acid sequence could be located between said second and third nucleic acid sequences, wherein the 5 'end of said fifth nucleic acid sequence is attached to the 3' end of said second nucleic acid sequence and the 3 'end of said fifth nucleic acid sequence is attached to the 5' end of said third nucleic acid sequence.
- said fifth nucleic acid sequence could be located in the region corresponding to the N-terminal end of the resulting fusion protein or between the product of interest and the dimerization domain.
- the DNA construct of the invention may also contain, if desired, a sixth nucleic acid sequence encoding a peptide capable of being used for recognition purposes.
- a sixth nucleic acid sequence encoding a peptide capable of being used for recognition purposes.
- Virtually any peptide or peptide sequence that allows recognition of the peptide or fusion protein can be used, for example, a peptide sequence recognized by a monoclonal antibody and which can serve to recognize the resulting illusion protein by immunodetection techniques, for example, tag peptides such as c-myc, HA, E, FLAG and, in general, any other sequence recognized by an antibody.
- Said sixth nucleic acid sequence may be located at any position of the DNA construct of the invention except in the region corresponding to the C-terminal end of HlyA to prevent the secretion signal from breaking.
- said sixth nucleic acid sequence could be located between said second and third nucleic acid sequences, wherein the 5 'end of said sixth nucleic acid sequence is attached to the 3' end of said second nucleic acid sequence and the 3 'end of said sixth nucleic acid sequence is attached to the 5' end of said third nucleic acid sequence.
- said sixth nucleic acid sequence could be located in the region corresponding to the N-terminal end of the resulting fusion protein or between the product of interest and the dimerization domain.
- Said fifth and sixth nucleic acid sequences may be separated from each other.
- said fifth and sixth nucleic acid sequences may be linked together.
- said sixth nucleic acid sequence encoding a peptide capable of being used for recognition purposes may be located between said third and fifth nucleic acid sequences, wherein the 5 'end of said sixth sequence of nucleic acid is attached to the 3 'end of said fifth nucleic acid sequence and the 3' end of said sixth nucleic acid sequence is attached to the 5 'end of said third nucleic acid sequence.
- said sequences may be linked together in the reverse order, in which case, said sixth nucleic acid sequence encoding a peptide capable of being used for recognition purposes is located between said second and fifth nucleic acid sequences, in wherein the 3 'end of said sixth nucleic acid sequence is attached to the 5' end of said fifth nucleic acid sequence and the 5 'end of said sixth nucleic acid sequence is attached to the 3' end of said second nucleic acid sequence .
- the DNA construct of the invention may further contain a nucleotide sequence that encodes an amino acid sequence that can be specifically cleaved by enzymatic or chemical means in order to release the dimeric protein of interest once isolated. fusion protein.
- the DNA construct of the invention may also include a seventh sequence of nucleic acid comprising a nucleotide sequence that encodes an amino acid sequence that can be specifically cleaved by enzymatic or chemical means.
- a seventh sequence of nucleic acid comprising a nucleotide sequence that encodes an amino acid sequence that can be specifically cleaved by enzymatic or chemical means.
- said seventh nucleic acid sequence comprises a nucleotide sequence encoding a protease recognition site, for example, an enterokinase, Arg-C endoprotease, Glu-C endoprotease, Lys-C endoprotease, Factor coagulation Xa and the like.
- said seventh nucleic acid sequence comprises a nucleotide sequence encoding a site that can be specifically cleaved by a chemical reagent such as, for example, cyanogen bromide that cleaves methionine residues or any other appropriate chemical reagent.
- Said seventh nucleic acid sequence is generally located next to the 3 'end of said second nucleic acid sequence, at any position between the second and third nucleic acid sequences, so that enzymatic or chemical means can be cleaved. dimer protein of interest.
- the DNA construct of the invention can be obtained by using techniques widely known in the state of the art [Sambrook et to the., "Molecular Cloning, a Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1989 Vol 1-3]. Said DNA construct of the invention may, operably linked, incorporate an expression regulatory sequence, thereby constituting an expression cassette.
- the invention provides at least one expression cassette comprising at least one DNA construct of the invention operably linked to an expression control sequence.
- Control sequences are sequences that control and regulate transcription and, where appropriate, the translation of the product of interest, and include promoter sequences (pT7, plac, pBAD, ptet, etc.), coding sequences for transcriptional regulators (jad, tetR, araC, etc.), ribosome binding sequences (RBS), and / or transcription terminator sequences (tlt2, etc.), etc.
- said expression control sequence is functional in bacteria, in particular, in Gram-negative bacteria.
- the DNA construct of the invention, or the expression cassette provided by this invention can be inserted into an appropriate vector.
- the invention relates to a vector, such as an expression vector, comprising at least one ⁇ DN construct or at least one expression cassette.
- a vector such as an expression vector
- the vector where said DNA sequence is introduced can be a plasmid or a vector that, when introduced into a host cell, is integrated or not into the gene a of said cell.
- the obtaining of said vector can be carried out by conventional methods known to those skilled in the art [Sambrok et al., 1989, cited supra].
- said vector further comprises a marker or gene that codes for a motif or for a phenotype that allows the selection of the host cell transformed with said expression cassette.
- the invention relates to a bacterium, in particular, a Gram negative bacterium, comprising at least one DNA construct of the invention or at least one expression cassette of the invention, or at least one vector of the invention. , hereinafter bacterium of the invention. Said bacterium must have the E.
- coli hemolysin (Hly) export system for which, if it is not native, the bacterium must be provided by transforming it with a vector containing the HlyB and HlyD genes, for example , plasmid pVDL9J [Fernández, LA et al., Applied and Environmental Microbiology, Nov. 2000, 5024-5029].
- plasmid pVDL9J plasmid pVDL9J
- Virtually any Gram negative bacteria for example, E. coli, Salmonella tiphymurium, Pseudomonas aeruginosa, Pseudomonas putida, etc., can be transformed with the DNA construct of the invention or with the expression cassette of the invention.
- the promoter, regulatory, marker and origins of replication signals must be optimized for each bacterial species.
- said Gram negative bacteria is Escherichia coli.
- the DNA construct of the invention can be used to produce products of interest. Therefore, in another aspect, the invention relates to a method for producing a product of interest, in the form of a dimeric fusion protein, which comprises growing a bacterium of the invention under conditions that allow the production and excretion to the culture medium of said product of interest in the form of a dimeric fusion protein.
- said dimeric fusion protein comprises two products of interest.
- a dimeric fusion protein would be obtained by expression of the nucleic acid sequences contained in at least one DNA construct of the invention, or at least one expression cassette of the invention, or at least one vector of the invention.
- the conditions to optimize the culture of the bacterium of the invention will depend on the bacteria used.
- the method of producing a product of interest provided by this invention further includes isolation and purification of said dimeric fusion protein.
- the DNA construct of the invention further includes said previously defined seventh nucleic acid sequence comprising a nucleotide sequence encoding an amino acid sequence capable of being specifically cleaved by enzymatic or chemical means in order to Release the product of interest.
- said nucleotide sequence encodes a protease recognition site, for example, an enterokinase, Arg-C endoprotease, Glu-C endoprotease, Lys-C endoprotease, Coagulation Factor Xa and the like.
- said nucleotide sequence encodes a site that can be specifically cleaved by a chemical reagent such as, for example, cyanogen bromide that cleaves methionine residues or any other appropriate chemical reagent.
- the invention relates to a dimeric fusion protein obtainable by expression of at least one nucleic acid sequence contained in at least one DNA construct of the invention, in which each monomer comprises: (i) the sequence of amino acids of a product of interest; (ii) an amino acid sequence corresponding to a dimerization domain; and (iii) the amino acid sequence of the E. coli HlyA or a fragment of said protein comprising the recognition signal of the secretion mechanism of the E. coli hemolysin (Hly) transport system.
- each dimeric fusion protein monomer of the invention comprises (i) a product of interest, for example, an enzyme, an enzyme inhibitor, a hormone, a molecule involved in cell adhesion and / or signaling and composed of domains, for example, an inoglobulin, an immunogenic antigen, such as a protein or an antigenic fragment thereof from a pathogen, for example, from a viral, bacterial, a parasite pathogen, etc., which may cause infections in humans or animals, a therapeutic agent, for example, a tumor specific antigen, an antigen of an autoimmune disease, etc., or an immunoregulatory molecule, for example, a growth factor, a cytokine, such like an interleukin, an interferon, etc .; in a particular embodiment, said product of interest is a mini-antibody capable of being used for therapeutic, diagnostic or research purposes; (ii) a dimerization domain, such as a peptide helix, a double coil wound structure (coiled coil), or,
- said dimerization domain comprises the leucine zipper of the yeast GCN4 transcription factor; and (iii) the complete amino acid sequence of E. coli HlyA, or alternatively, an E. coli HlyA fragment comprising the recognition signal of the secretion mechanism of the E. coli Hly transport system.
- Each dimeric fusion protein monomer of the invention may also contain, if desired, (a) a spacer peptide between the product of interest and the dimerization domain; advantageously, said spacer peptide is a structurally flexible peptide, for example, a peptide containing amino acid residue repeats, such as Gly-Gly-Gly-Ser, or any other suitable amino acid residue repeat, or the hinge region of an antibody; in a particular embodiment, said flexible spacer peptide comprises the hinge region of a antibody; and / or (b) a peptide to facilitate the isolation or purification of the peptide or fusion protein, for example, a polyhistidine sequence, or a peptide sequence recognized by a monoclonal antibody and which can serve to purify the resulting fusion protein by immunoafmity chromatography, for example, tag peptides such as c-myc, HA, E, FLAG, and, in general, any other sequence recognized by an antibody; and / or (c) a
- the dimeric fusion protein production system provided by this invention is particularly useful for the production of proteins involved in a binding activity, for example, in protein-DNA or antigen-antibody interactions, since it can intensify its greediness.
- the DNA constructs of the invention serve for the creation and expression of a library of dimeric proteins, for example of mini-antibodies.
- a particular example of this embodiment would be to use the mini-antibody dimers thus produced in processes of selecting molecules with binding capacity to a particular antigen.
- the dimeric protein production system serves for the production of heterodimers between two molecules with binding capacity for different antigens or different epitopes of the same antigen, preferably two mini-antibodies, or a mini-antibody and another type of molecule, as can be, but is not limited to, a toxin, an antitumor drug, an enzyme or molecules involved in marking or detection.
- a particular example of this embodiment would be to use these dimers for tumor cell mapping or the transport of molecules with antitumor activity to the tumor.
- the production of this type of heterodimers presents important applications in diagnosis and therapy.
- An advantage of the system provided by this invention is that it allows the production of toxic proteins for a bacterial host.
- EXAMPLE 1 Production of dimeric mini-antibodies with high affinity secreted by the hemolysin transport system (Hly) of E. coli
- Hly hemolysin transport system
- This example describes the secretion of dimeric mini-antibodies in supernatants of E. coli cultures using the hemolysin transport system (Hly)
- dimerization can be achieved by genetic engineering in the transport system of the Hly.
- an amphipathic ⁇ -helix that is, the leucine zipper domain of the yeast transcription factor GCN4
- VHHlyA the resulting polypeptide
- the vectors derived from ⁇ HlyA and 'ZEHIyA were then used for the secretion of the VHH domains of immunoglobulins obtained from camel antibodies.
- the hybrids V HH -EHlyA and V HH- ZEHI A were secreted and found in the extracellular medium as monomers and dimers, respectively.
- the Vmi-ZEHlyA dimeric molecules showed superior binding properties to their related antigen, with a 10-fold increase in their functional affinity (avidity). This procedure allows to easily obtain miniantibodies V HH monomeric and dimeric with high avidity from culture supernatants of E. coli, facilitating thus the selection and purification of high performance of V HH clones from large libraries.
- Plasmid pZEHly ⁇ ( ⁇ p 1 ) was obtained by inserting into the single site I left pEHly ⁇ a fragment of ⁇ DN of 170 bp encoding the amplified ZIP domain by PCR and digested with Sal ⁇ .
- the plasmid map pZEHlyA is shown in Figure 6.
- Plasmid pZEHly ⁇ 2-SD (Ap 1 ) was obtained by inserting into the single S ⁇ I site of pEHly ⁇ 2-SD the 170 bp ⁇ DN fragment encoding ZIP obtained by digestion with San of pZEHlyA.
- the plasmid pZEHly ⁇ 2-SD map is shown in Figure 7.
- the orientation of the ZIPDN ZIP fragment that produced an internal insertion in the E-labeled C-HlyA domain of pZEHlyA and pZEHlyA2-SD after ⁇ DN sequencing was selected.
- the approximately 0.3 kb DNA fragments encoding the VH H , Vamy YV to domains were amplified by PCR with Vent DNA polymerase, using as template 1 ng of the phagemid A100R3A2 (anti- ⁇ -amylase) or R3E5 ( tetanus vaccine), respectively, and as primers the oligonucleotides identified as SEQ ID NO: 7 and SEQ ID NO:
- the amplified DNA products encoding V amy and V ⁇ t ⁇ contained the flanking restriction sites Ncol and Sfi ⁇ , which allowed their cloning at the same sites of pEHlyA2-SD and pZEHlyA2-SD, thus generating pV ⁇ HlyA, pV to HlyA, pN ⁇
- the plasmid maps V ⁇ lyA and pV ⁇ J , ZhlyA are shown in Figures 8 and 9, respectively.
- Phagemids A100R3A2 and R3E5 were provided by Dr. Hennie Hoogenboon (Dyax Co., USA). Both phagemids are derived from pCA ⁇ TAB6 (Cambridge Research Biochemicals) that contain the V HH domains of cloned camelids between the S ⁇ l and Not ⁇ sites.
- Electrophoresis and immunoblotting of proteins were carried out on sodium dodecyl sulfate-po liacrylamide gels (SDS-PAGE) using 4% stacking and 10% separation gels (acrylamide: bisacrylamide 29: 1; Bio-Rad), using the system of Miniprotean® (Bio-Rad) electrophoresis and following the standard protocols [Ausubel, FM, R. Brent, RE guitarist, DD Moore, JG Seidman, JA Smith, and K. Struhl 1994. Current Protocols in Molecular Biology. John Wiley & Sons, ew York; Fraile, S., F. Roncal, LA Fernandez, and V. de Lorenzo 2001.
- the membrane was blocked in MTP buffer (3% w / v skim milk, 0.1% v / v tween 20 in PBS) and the E-labeled polypeptides were detected with peroxidase-labeled anti-E monoclonal antibody (0, 2 ⁇ g / ml in MTP buffer; Amersham Bioscience).
- the bound antibody-POD conjugate was revealed by chemilumimscence, as already described [Fraile, S., F. Roncal, LA Fernandez, and V. de Lorenzo 2001.
- the culture supernatants (approximately 0.2 ml) containing PBS IX were mixed with 2 mg of standard protein of known mass (dissolved in 60 ⁇ l of H 2 O) and passed through a Bio-Gel ⁇ resin of l, 5m (Bio-Rad) packed in a column 1 m long and 1.5 cm wide (Bio-Rad).
- the gel filtration patterns (Bio-Rad) were thyroglobulin (PM 670,000), bovine gammobulbulin (PM 158,000), chicken ovalbumin (PM 44,000), equine myoglobin (PM 17,000) and vitamin B-12 ( PM 1J50).
- the flow rate of the sample through the column was set at 0.2 ml / min using a peristaltic pump (Pl, Amersham Bioscience).
- the vacuum volume of the column was calculated by elution of dextran blue 2000 (Amersham Bioscience). Elution of protein patterns through the column was monitored by UN light absorption (Uvicord S LT, Amersham Bioscience). He collected 1 ml fractions (RediFrac collector, Amersham Bioscience) and concentrated 10 times by precipitation with 10% trichloroacetic acid (TCA) and 10 ⁇ g bovine serum albumin (BSA, Roche) that acted as a transporter. The presence of E-labeled HlyA proteins in these fractions was detected by Western blotting using a POD-labeled anti-E monoclonal antibody (see above).
- Enzyme-linked immunosorbent assays ELISA.
- the antigens ( ⁇ -amylase or ovalbumin; Sigma) were adsorbed for 1 h at 37 ° C to 96-well microtiter immunoplates (Maxisorb, Nunc) at 200 ⁇ g / ml in PBS. The excess antigen was washed and the plates were blocked for 16 h at 4 ° C in MTP buffer (see above).
- the mini-antibodies were diluted in MTP buffer, added to the wells at the concentrations indicated in each case and incubated for 1 h at room temperature. Next, unbound antibodies were removed by four washes of the wells with PBS containing 0.1% Tween 20 (v / v).
- the POD-labeled anti-E monoclonal antibody conjugate (0.2 ⁇ g / ml in MTP buffer) was added to the wells and further incubated for 1 h at room temperature to detect the bound E-labeled mini-antibodies, after washing as before, Plaques were revealed using o-phenylenediamine (Sigma). The reaction was allowed to continue for 10 minutes in the dark, stopped with 0.6 N HCl and the OD was determined at 490nm of the wells (Benchmark microplate reader, Bio-Rad).
- Miniantibodies use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli Biochemistry. 31: 1579-84] for insertion in C-HlyA.
- the ZIP domain consists of an amphipathic helix that forms the leucine zipper of the GCN4 yeast transcription factor, flanked at its N-terminal end by a peptide hinge zone derived from the mouse IgG3, and at its C-terminal end by a marker of polyhistidine (6xhis).
- a DNA fragment encoding the ZIP domain was inserted internally near the N-terminal end of the approximately 27 kDa E-labeled version of C-HlyA (EHlyA) present in the plasmid pEHlyA ( Figure 1A).
- the resulting plasmid, pZEHlyA codes for a polypeptide of approximately 33 kDa (called ZEHlyA) containing the ZIP and C-HlyA domains labeled with E ( Figures 1A and IB).
- the production of ZEHlyA and EHlyA, as a control without ZLP, was induced in cultures of wild-type TolC + cells of E.
- ZEHlyA showed an apparent Mr of approximately 66 kDa on gel filtration chromatography, while EHlyA had an apparent Mr of approximately 32 kDa under the same conditions. It is important that a single peak be detected for each protein (Figure 3B), which indicates that both polypeptides were present as monomers (EHlyA) and dimers (ZEHlyA) stable in solution. Taken together, these results demonstrated that protein dimerization could be obtained by incorporating unfriendly helices into C-HlyA without interfering with its secretion by the Hly transporter.
- pZEHlyAJ-SD a plasmid, called pZEHlyAJ-SD, was constructed to generate internal fusions between recombinant antibody fragments that lack the N-SP and ZEHlyA domain.
- This plasmid is a derivative of pEHlyA2-SD [Fernández, LA, I. Sola, L. Enjuanes, and V. de Lorenzo 2000.
- camel V HH co antibodies or fusion pairs were due to their small size (approximately 15 kDa) and their low tendency to form protein aggregates [Muyldermans, S. 2001. Single domain camel antibodies: current status J Biotechnol. 74: 277-302; Plückthun, A., and P. Pack 1997. New protein engineering approaches to multivalent and bispecific antibody fragments Immunotechnology. 3: 83- 105], which could interfere with the dimerization analysis obtained by the ZIP domain (see Discussion). E.
- coli HB2151 cells (pNDL9J) were transformed with a plasmid encoding the hybrid N HH- HlyA (N ⁇ ⁇ HlyA, pN ⁇ OT ⁇ ZHlyA, pN te HlyA or pN ttf ZHlyA) and induced 4 h by adding 0.3 mM PTG to liquid cultures grown in LB at 30 or 37 ° C.
- the secreted polypeptides N ⁇ m? HlyA and N roj ZHlyA were subsequently detected in the supernatants of the corresponding cultures of E. coli by Western blotting with POD-labeled anti-monoc monoclonal antibody ( Figure 4C).
- V HH camel antibodies can be produced by fusing them to the ⁇ HlyA or Z ⁇ HlyA moieties, respectively.
- dimerization improved the functional binding properties of N ⁇ ZHly ⁇ .
- the binding to the ⁇ -amylase of V a ⁇ m , A ⁇ yA monomeric and V ⁇ m , dimeric ZHlyA was compared by ELISA.
- serial dilutions of E. coli culture supernatants containing identical amounts of V ⁇ mj , HlyA or V to ⁇ ZHlyA were incubated with ELISA plates coated with ⁇ -amylase or ovalbumin (as a control antigen).
- DISCUSSION Dimerization is a property that is often desired to be engineered in proteins when binding activity is involved (for example, in protein-DNA or antigen-antibody interactions), since it can enhance its functional affinity (avidity).
- This example illustrates the genetic engineering, for the first time, of the dimerization of the proteins secreted by the E. coli hemolysin transport system and that technology has been used to produce high avidity mini-antibodies derived from camel V antibodies.
- HH - The results obtained demonstrate that the incorporation of an amphipathic autodimerization helix at the N-terminus of C-HlyA does not interfere with the secretion of Hly and allows the dimerization of the secreted polypeptide.
- dimerization can intensify the avidity of the binding of the secreted polypeptide derived from C-HlyA.
- it can also have other applications, such as the molecular association of various antigens and / or adjuvants produced by live bacterial strains, or the combination of various biological activities for the generation of bispecific molecules (for example, antigen binding and recruitment of the complement).
- Highly avid dimeric scFvs have been produced in the periplasm of E. coli cells by inserting antipathic helices at their C-terminal end. Due to the tendency of some scFvs to form dimers and aggregates of high molecular weight proteins, smaller antibody fragments were used.
- V HH camel antibodies have received a lot of attention due to their better solubility and their simpler structure, which facilitates their amplification and cloning. It is worth noting that the changes made do not diminish the affinity or specificity of the V HH camel antibodies, due to the presence of extremely variable complementarity determining regions (CDRs) that compensate for the loss of diversity caused by the absence of a VL domain Camel antibodies have also demonstrated extraordinary potential as enzyme inhibitors since their large CDRs can reach the active sites hidden in enzymes. In addition, the similarity between the VHH camel antibodies and the human VH3 family sequences is allowing the generation of libraries presented in phages of the camelized human V H domains and the humanized V H H camel antibodies.
- CDRs complementarity determining regions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/566,827 US20080280346A1 (en) | 2003-07-31 | 2004-07-19 | System For the Production of Dimeric Proteins Based on the Transport System of Hemolysin of Escherichia Coli |
EP04742091A EP1655371A1 (en) | 2003-07-31 | 2004-07-19 | System for the production of dimeric proteins based on the transport system of hemolysin of escherichia coli |
CA002534299A CA2534299A1 (en) | 2003-07-31 | 2004-07-19 | System for producing dimeric proteins based on the escherichia coli hemolysin transport system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200301830 | 2003-07-31 | ||
ES200301830A ES2296423B1 (es) | 2003-07-31 | 2003-07-31 | Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005012532A1 true WO2005012532A1 (es) | 2005-02-10 |
Family
ID=34112523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2004/070053 WO2005012532A1 (es) | 2003-07-31 | 2004-07-19 | Sistema para la producción de proteínas diméricas basado en el sistema de transporte de hemolisina de escherichia coli |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080280346A1 (es) |
EP (1) | EP1655371A1 (es) |
CA (1) | CA2534299A1 (es) |
ES (1) | ES2296423B1 (es) |
WO (1) | WO2005012532A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101965362A (zh) * | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
EP2670779B1 (en) * | 2011-02-01 | 2017-08-02 | Bac Ip B.V. | Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies |
JP2014530009A (ja) * | 2011-09-29 | 2014-11-17 | エーピーオー‐ティー ビー.ヴイ. | 異常細胞を標的とする多重特異性結合分子 |
CA2860914A1 (en) | 2012-01-13 | 2013-07-18 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN113238053B (zh) * | 2021-04-30 | 2022-05-13 | 四川大学华西医院 | 一种用于检测stat3二聚化的质粒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987006953A1 (en) * | 1986-05-15 | 1987-11-19 | Ian Barry Holland | Process for the production of a polypeptide |
-
2003
- 2003-07-31 ES ES200301830A patent/ES2296423B1/es not_active Expired - Fee Related
-
2004
- 2004-07-19 EP EP04742091A patent/EP1655371A1/en not_active Withdrawn
- 2004-07-19 CA CA002534299A patent/CA2534299A1/en not_active Abandoned
- 2004-07-19 US US10/566,827 patent/US20080280346A1/en not_active Abandoned
- 2004-07-19 WO PCT/ES2004/070053 patent/WO2005012532A1/es active Search and Examination
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987006953A1 (en) * | 1986-05-15 | 1987-11-19 | Ian Barry Holland | Process for the production of a polypeptide |
Non-Patent Citations (3)
Title |
---|
FERNANDEZ L.A. ET AL.: "Specific secretion of active single-chain Fv antibodies into the supernatants of Escherichia coli cultures by use of the hemolysin system", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 66, no. 11, November 2000 (2000-11-01), pages 5024 - 5029, XP002371602 * |
FRAILE S. ET AL.: "Secretion of proteins with dimerization capacity by the haemolysin type I transport system of Escherichia coli", MOLECULAR MICROBIOLOGY, vol. 53, no. 4, August 2004 (2004-08-01), pages 1109 - 1121, XP003000853 * |
PACK P. ET AL.: "Miniantibodies: use of amphipatic helice to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli", BIOCHEMISTRY, vol. 31, no. 6, 18 February 1992 (1992-02-18), pages 4579 - 1584, XP002026334 * |
Also Published As
Publication number | Publication date |
---|---|
ES2296423A1 (es) | 2008-04-16 |
US20080280346A1 (en) | 2008-11-13 |
CA2534299A1 (en) | 2005-02-10 |
ES2296423B1 (es) | 2009-03-16 |
EP1655371A1 (en) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2335136T3 (es) | Expresion fagica mediante translocacion cotraduccional de polipeptidos de fusion. | |
ES2306794T3 (es) | Moleculas de autoensamblaje. | |
Lai et al. | The T-pilus of Agrobacterium tumefaciens | |
EP0654085B1 (en) | Monomeric and dimeric antibody-fragment fusion proteins | |
de Gier et al. | Assembly of a cytoplasmic membrane protein in Escherichia coli is dependent on the signal recognition particle | |
ES2536509T3 (es) | OB-fold usado como estructura para diseño por ingeniería de nuevos agentes de unión específicos | |
Facey et al. | Biogenesis of bacterial inner-membrane proteins | |
ES2661404T3 (es) | Métodos para la expresión de péptidos y proteínas | |
ES2268376T3 (es) | Etiqueta proteica que comprende un dominio de biotinilacion y procedimiento para aumentar la solubilidad y determinar el estado de plegamiento. | |
ES2296423B1 (es) | Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones. | |
Jacob‐Dubuisson et al. | Amino‐terminal maturation of the Bordetella pertussis filamentous haemagglutinin | |
Canali et al. | A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope | |
CN103497253A (zh) | 一种针对h2a.z变体的纳米抗体、其编码序列及应用 | |
CN111269324B (zh) | 高斯荧光素酶和地高辛单链抗体的融合蛋白及其应用 | |
CN107365732A (zh) | 一种抗TNF‑α纳米抗体及其基因工程表达 | |
AR044603A1 (es) | Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones | |
Chung et al. | Export of recombinant proteins in Escherichia coli using ABC transporter with an attached lipase ABC transporter recognition domain (LARD) | |
ES2612545T3 (es) | Sistema de expresión del operón melibiosa | |
Ye et al. | High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli | |
JP2011178691A (ja) | カテニン結合プローブとその用途 | |
ES2792350T3 (es) | Secuencia señal secretora de organismos eucariotas para la expresión recombinante en organismos procariotas | |
ES2674983T3 (es) | Método para la separación de proteínas que contienen un dominio que se une a albúmina | |
Martsev et al. | Antiferritin single‐chain antibody: a functional protein with incomplete folding? | |
ES2301262B1 (es) | Generacion de adhesion especifica en bacterias gram negativas mediante el anclaje de monodominos de inmunoglobulinas en su superficie con autotransportadores. | |
CN106928358A (zh) | 一种CD105纳米抗体Nb168 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2534299 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004742091 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10566827 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004742091 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) |